Key result
Dystrophic muscle exhibits reduced PKA activity driven by mislocalized myospryn and regulatory subunits.
Why the study?
Alterations in signaling pathway activity and the role of myospryn in Duchenne muscular dystrophy pathogenesis were not fully understood.
Answers are grounded in this paper and cite their sources.
May implicate costameric signaling in DMD cardiomyopathy; leaves open therapeutic targeting pending validation.
Alterations in signaling pathway activity have been implicated in the pathogenesis of Duchenne muscular dystrophy, a degenerative muscle disease caused by a deficiency in the costameric protein dystrophin. Accordingly, the notion of the dystrophin-glycoprotein complex, and by extension the costamere, as harboring signaling components has received increased attention in recent years. The localization of most, if not all, signaling enzymes to this subcellular region relies on interactions with scaffolding proteins directly or indirectly associated with the dystrophin-glycoprotein complex. One of these scaffolds is myospryn, a large, muscle-specific protein kinase A (PKA) anchoring protein or AKAP. Previous studies have demonstrated a dysregulation of myospryn expression in human Duchenne muscular dystrophy, suggesting a connection to the pathophysiology of the disorder. Here we report that dystrophic muscle exhibits reduced PKA activity resulting, in part, from severely mislocalized myospryn and the type II regulatory subunit (RIIalpha) of PKA. Furthermore, we show that myospryn and dystrophin coimmunoprecipitate in native muscle extracts and directly interact in vitro. Our findings reveal for the first time abnormalities in the PKA signal transduction pathway and myospryn regulation in dystrophin deficiency.
No takes yet. Share an insight, caveat, or question.
Reynolds et al. (2008) studied Duchenne muscular dystrophy. Dystrophin deficiency was evaluated on PKA activity and myospryn localization. Dystrophic muscle exhibits reduced PKA activity resulting from severely mislocalized myospryn and the type II regulatory subunit of PKA, revealing abnormalities in the PKA signal transduction pathway.
Synapse has enriched 10 related papers. Consider them for comparative context: